ERBB2 and breast carcinoma: Trastuzumab is a humanized monoclonal antibody against the extracellular domain of an oncoprotein identified as human epidermal growth factor receptor 2 (HER2/ERbB2), which is highly relevant in prognosis in breast cancer (32–35).